A Randomized, Control,Open Label, Multicentre Clinical Study to Evaluate the Efficacy and Safety of Cilostazol and Probucol Alone and in Combination on Atherosclerosis Related Biomarker.
Phase of Trial: Phase IV
Latest Information Update: 14 Oct 2017
At a glance
- Drugs Cilostazol (Primary) ; Probucol (Primary)
- Indications Arteriosclerosis obliterans; Embolism and thrombosis
- Focus Biomarker; Therapeutic Use
- 16 Jan 2010 Planned end date changed from 1 Jul 2009 to 1 Mar 2010 as reported by ClinicalTrials.gov
- 27 Aug 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov
- 22 Jan 2009 New trial record.